Skip to main content

Sequenom Q2 Revenues Flat, Losses Narrow

NEW YORK, July 29 - Sequenom reported flat revenues for the second quarter today, amid narrowed net losses.

The San Diego company had revenues of $7.7 million for the quarter, compared to revenues of $7.7 million for the same period last year.


R&D expenses came to $6.5 million, compared to $8.1 million for the year-ago quarter.


The company's net loss narrowed to $9.3 million, from $15 million in the second quarter of 2002.


As of June 30, Sequenom had $82.9 million in cash, cash equivalents, short-term investments, and restricted cash.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.